ASCP Annual Meeting 2026 — Abstracts

[Session] — | 1 | [Session] [NOVEL TARGETS AND TREATMENTS FOR STIMULANT USE DISORDERS AND DEPRESSION](001-novel-targets-and-treatments-for-stimulant-use-disorders-and.md) | Keren Bachi | | 2 | [SOCIAL-NEUROBEHAVIORAL PHENOTYPES FOR ADVANCEMENT OF SOCIAL-TARGET INTERVENTION IN COCAINE USE DISORDER](002-social-neurobehavioral-phenotypes-for-advancement-of-social.md) | Keren Bachi | | 3 | [FEASIBILITY AND PRELIMINARY EFFICACY OF TIRZEPATIDE FOR INDIVIDUALS WITH MODERATE/SEVERE METHAMPHETAMINE USE DISORDER](003-feasibility-and-preliminary-efficacy-of-tirzepatide-for-indi.md) | Manish Jha | | 4 | [ACCELERATED COURSE OF INTERMITTENT THETA BURST FOR METHAMPHETAMINE USE DISORDER: FEASIBILITY AND EEG-DERIVED FUNCTIONAL CONNECTIVITY CORRELATES OF TREATMENT RESPONSE](004-accelerated-course-of-intermittent-theta-burst-for-methamphe.md) | Nabila Haque | | 5 | [INTEGRATING COGNITIVE-BEHAVIORAL THERAPY WITH REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (CBT/TMS): A NOVEL COMBINED NEUROMODULATION-PSYCHOTHERAPY MODEL FOR PRENATAL DEPRESSION](005-integrating-cognitive-behavioral-therapy-with-repetitive-tra.md) | Rana Jawish | | 6 | [Session] [CONDUCTING CLINICAL TRIALS USING COMBINED TREATMENT MODALITIES: CHALLENGES, OPPORTUNITIES, AND INSIGHTS FOR FUTURE REGULATORY CONSIDERATION](006-conducting-clinical-trials-using-combined-treatment-modaliti.md) | Samuel Wilkinson | | 7 | [COGNITIVE BEHAVIORAL THERAPY FOLLOWING ESKETAMINE FOR MAJOR DEPRESSION AND SUICIDAL IDEATION FOR RELAPSE PREVENTION: THE CBT-ENDURE STUDY](007-cognitive-behavioral-therapy-following-esketamine-for-major.md) | Samuel Wilkinson | | 8 | [INTERIM DATA FROM A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ACCELERATED TRANSCRANIAL MAGNETIC INTERMITTENT THETA-BURST STIMULATION AND ADJUNCTIVE D-CYCLOSERINE FOR SUICIDAL IDEATION](008-interim-data-from-a-randomized-placebo-controlled-trial-of-a.md) | Alexander McGirr | | 9 | [SYNERGISTIC BIOBEHAVIORAL TREATMENTS TO REDUCE DEPRESSION AND COMPULSIVITY](009-synergistic-biobehavioral-treatments-to-reduce-depression-an.md) | Shabnam Hossein | | 10 | [Session] [NOVEL THERAPEUTICS WITH ENTACTOGENIC EFFECTS - A NEW FRONTIER FOR MOOD AND ANXIETY DISORDERS?](010-novel-therapeutics-with-entactogenic-effects-a-new-frontier.md) | Hiroe Hu | | 11 | [EMP-01 (R-MDMA) AS A NEXT-GENERATION ENTACTOGEN: MECHANISTIC RATIONALE AND THERAPEUTIC POTENTIAL IN SOCIAL ANXIETY DISORDER](011-emp-01-r-mdma-as-a-next-generation-entactogen-mechanistic-ra.md) | Sarah McEwen | | 12 | [INTRAVENOUS KETAMINE IMPROVES SOCIAL ANHEDONIA IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION AND SUICIDAL IDEATION](012-intravenous-ketamine-improves-social-anhedonia-in-patients-w.md) | Hiroe Hu | | 13 | [KETAMINE’S POTENTIAL FOR TREATING LONELINESS IN TREATMENT RESISTANT BIPOLAR DEPRESSION](013-ketamine-s-potential-for-treating-loneliness-in-treatment-re.md) | Diana Orsini | | 14 | [OBJECTIVE MEASURES OF EMPATHY: PROSOCIAL LEARNING AND MOOD STATES](014-objective-measures-of-empathy-prosocial-learning-and-mood-st.md) | Yoojin Lee | | 15 | [Session] [TARGETED INTERVENTIONS FOR SUICIDE PREVENTION](015-targeted-interventions-for-suicide-prevention.md) | Jill Harkavy-Friedman | | 16 | [USING INTENSIVE, REAL-TIME MONITORING DESIGNS TO IDENTIFY PROXIMAL RISK FACTORS FOR SUICIDAL IDEATION AMONG ADOLESCENTS](016-using-intensive-real-time-monitoring-designs-to-identify-pro.md) | Jessica Hamilton | | 17 | [CHANGES IN SYMPTOMS OF SUICIDAL IDEATION AND RELATED SYMPTOMS WITH TIRZEPATIDE IN INDIVIDUALS WITH MODERATE-TO-SEVERE METHAMPHETAMINE USE DISORDER](017-changes-in-symptoms-of-suicidal-ideation-and-related-symptom.md) | Snoben Kuruvila | | 18 | [PSYCHOSOCIAL INTERVENTIONS FOR OLDER ADULTS WITH DEPRESSION AND VARYING DEGREES OF COGNITIVE FUNCTIONING AFTER A SUICIDE-RELATED HOSPITALIZATION](018-psychosocial-interventions-for-older-adults-with-depression.md) | Dimitris Kiosses | | 19 | [EFFICACY AND SAFETY OF A SINGLE DOSE OF PSILOCYBIN FOR CHRONIC ACTIVE SUICIDAL IDEATION: EXPERIENCES IN AN OPEN LABEL TRIAL](019-efficacy-and-safety-of-a-single-dose-of-psilocybin-for-chron.md) | Scott Aaronson | | 20 | [Session] [IMPROVING METABOLIC HEALTH IN MENTAL ILLNESS: A TRANSDIAGNOSTIC APPROACH](020-improving-metabolic-health-in-mental-illness-a-transdiagnost.md) | Mahavir Agarwal | | 21 | [PSYMETRIC 2.0: DEVELOPMENT, REFINEMENT AND EXTERNAL VALIDATION OF CLINIC-READY CARDIOMETABOLIC PREDICTION MODELS FOR YOUNG PEOPLE WITH PSYCHOSIS SPECTRUM DISORDERS](021-psymetric-2-0-development-refinement-and-external-validation.md) | Benjamin Perry | | 22 | [TREATING PSYCHOTROPIC ASSOCIATED WEIGHT GAIN IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITY: A RETROSPECTIVE CHART REVIEW STUDY](022-treating-psychotropic-associated-weight-gain-in-individuals.md) | Nicolette Stogios | | 23 | [PTSD AND DIABETES: A TWO-WAY STREET IN METABOLIC AND MENTAL HEALTH](023-ptsd-and-diabetes-a-two-way-street-in-metabolic-and-mental-h.md) | Katharine Liang | | 24 | [PMCID: PMC7170451.](024-pmcid-pmc7170451.md) | Powers A | | 25 | [Session] [STRATEGIES TO IMPROVE TREATMENT EFFECT DETECTION IN MDD TRIALS](025-strategies-to-improve-treatment-effect-detection-in-mdd-tria.md) | George Papakostas | | 26 | [STRATEGIES TO IMPROVE TREATMENT EFFECT DETECTION IN MDD TRIALS](026-strategies-to-improve-treatment-effect-detection-in-mdd-tria.md) | Clotilde Guidetti | | 27 | [FUNCTIONAL CONNECTIVITY OF THE STRIATUM AS A BIOMARKER OF TREATMENT RESPONSE TO KCNQ-TARGETED AGENTS IN DEPRESSION](027-functional-connectivity-of-the-striatum-as-a-biomarker-of-tr.md) | James Murrough | | 28 | [DEPRESSION AND DISTURBANCES IN CIRCADIAN RHYTHMS: PATHWAYS FOR NOVEL TREATMENT DEVELOPMENT](028-depression-and-disturbances-in-circadian-rhythms-pathways-fo.md) | Emmanuel Mignot | | 29 | [TOWARDS AN INTERNATIONAL, STANDARDIZED MODEL PSYCHOPHARMACOLOGY CURRICULUM FOR PSYCHIATRY RESIDENCY TRAINING: A COMPETENCY-BASED FRAMEWORK FOR IMPLEMENTATION](029-towards-an-international-standardized-model-psychopharmacolo.md) | Matthew Macaluso | | 30 | [THE ASCP MODEL PSYCHOPHARMACOLOGY CURRICULUM UPDATE](030-the-ascp-model-psychopharmacology-curriculum-update.md) | Richard Shelton | | 31 | [TOWARDS AN INTERNATIONAL, STANDARDIZED MODEL PSYCHOPHARMACOLOGY CURRICULUM FOR PSYCHIATRY RESIDENCY TRAINING: A COMPETENCY-BASED FRAMEWORK FOR IMPLEMENTATION](031-towards-an-international-standardized-model-psychopharmacolo.md) | Gemma Espejo | | 32 | [TOWARDS AN INTERNATIONAL, STANDARDIZED MODEL PSYCHOPHARMACOLOGY CURRICULUM FOR PSYCHIATRY RESIDENCY TRAINING: A COMPETENCY-BASED FRAMEWORK FOR IMPLEMENTATION](032-towards-an-international-standardized-model-psychopharmacolo.md) | Keanna Lee | | 33 | [RE104: A NOVEL SEROTONERGIC PSYCHEDELIC 4-OH-DIPT PRODRUG FOR THE TREATMENT OF POSTPARTUM DEPRESSION](033-re104-a-novel-serotonergic-psychedelic-4-oh-dipt-prodrug-for.md) | Mark Pollack1 | | 34 | [A NEW DAWN FOR SOCIAL ANXIETY TREATMENT: CLINICAL ADVANCEMENT OF THE NOVEL V1AR ANTAGONIST, NTX-1472](034-a-new-dawn-for-social-anxiety-treatment-clinical-advancement.md) | Tiffany Lago1 | | 35 | [DT-101 – A NOVEL ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE RECEPTOR (AMPAR) POSITIVE ALLOSTERIC MODULATOR DEMONSTRATES FAVORABLE TOLERABILITY AND FUNCTIONAL BIOMARKERS IN PHASE 1 HEALTHY VOLUNTEER TRIAL](035-dt-101-a-novel-alpha-amino-3-hydroxy-5-methyl-4-isoxazole-re.md) | Simon Ward1 | | 36 | [SELTOREXANT, ADJUNCTIVE TO ANTIDEPRESSANTS, IN ADULTS WITH MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS: PHASE 3 STUDIES](036-seltorexant-adjunctive-to-antidepressants-in-adults-with-maj.md) | Gahan Pandina1 | | 37 | [KETAMINE TREATMENT FOR NON-MOTOR SYMPTOMS OF PARKINSON'S DISEASE](037-ketamine-treatment-for-non-motor-symptoms-of-parkinson-s-dis.md) | Gerard Sanacora1 | | 38 | [FORVISIRVAT (SP-624), A FIRST-IN-HUMAN SIRT6 ACTIVATOR WITH AN EPIGENETIC MECHANISM OF ACTION, CURRENTLY IN A PHASE 2B-3 STUDY FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER](038-forvisirvat-sp-624-a-first-in-human-sirt6-activator-with-an.md) | Joel Raskin1 | | 39 | [UNLOCKING MEDICINES FOR NEUROPSYCHIATRY BY ENHANCING ORAL ABSORPTION USING A LYMPHATIC-TARGETING PRODRUG TECHNOLOGY](039-unlocking-medicines-for-neuropsychiatry-by-enhancing-oral-ab.md) | Antony Loebel1 | | 40 | [BH-200 (NELIVAPTAN), A VASOPRESSIN V1B RECEPTOR ANTAGONIST, IN GENETICALLY DEFINED SUBGROUPS OF MDD: PRECISION TARGETING OF HPA-AXIS DYSREGULATION IN THE OLIVE PHASE 2 PROGRAM](040-bh-200-nelivaptan-a-vasopressin-v1b-receptor-antagonist-in-g.md) | Daniel Gehrlach1 | | 41 | [NOVEL ORAL RAPID-ACTING NEUROACTIVE STEROID FOR TREATMENT OF POSTPARTUM DEPRESSION: A PLACEBO-CONTROLLED PHASE 3 CLINICAL TRIAL OF LPCN 1154A](041-novel-oral-rapid-acting-neuroactive-steroid-for-treatment-of.md) | Anthony DelConte1 | | 42 | [A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE FATTY ACID AMIDE HYDROLASE INHIBITOR PALMITOYLETHANOLAMIDE IN BIPOLAR DEPRESSION](042-a-randomized-placebo-controlled-trial-of-the-fatty-acid-amid.md) | Rodrigo Machado-Vieira1 | | 43 | [PROSPECTIVE REPLICATION OF AN EEG BIOMARKER FOR PREDICTING CHANGES IN ATTENTION IN ALTO-203, AN H3 INVERSE AGONIST](043-prospective-replication-of-an-eeg-biomarker-for-predicting-c.md) | Joshua Jordan1 | | 44 | [Session] [FINDINGS FROM THE ASCP PRESIDENTIAL TASK FORCE ON PSYCHOTROPIC DRUG POLYPHARMACOTHERAPY](044-findings-from-the-ascp-presidential-task-force-on-psychotrop.md) | Joseph Goldberg | | 45 | [UNDERUTILIZED AUGMENTERS IN POLYPHARMACY REGIMENS: THE CASE FOR LITHIUM](045-underutilized-augmenters-in-polypharmacy-regimens-the-case-f.md) | Nassir Ghaemi | | 46 | [RATIONAL AND IRRATIONAL PSYCHOPHARMACOLOGY COMBINATIONS](046-rational-and-irrational-psychopharmacology-combinations.md) | Joseph Goldberg | | 47 | [WHEN TO SWITCH VERSUS AUGMENT PHARMACOTHERAPIES](047-when-to-switch-versus-augment-pharmacotherapies.md) | Snoben Kuruvila | | 48 | [MONDO COMBO: DO COMBINATIONS OF ANTIPSYCHOTICS EVER MAKE ANY SENSE?](048-mondo-combo-do-combinations-of-antipsychotics-ever-make-any.md) | Leslie Citrome | | 49 | [COMORBIDITY POLYPHARMACY: SIMULTANEOUS VS. SUCCESSIVE INTRODUCTION OF CO-PHARMACOTHERAPIES](049-comorbidity-polypharmacy-simultaneous-vs-successive-introduc.md) | Anita Clayton | | 50 | [SAFETY, TOLERABILITY, AND DRUG-DRUG INTERACTION CONCERNS IN POLYPHARMACOLOGY REGIMENS](050-safety-tolerability-and-drug-drug-interaction-concerns-in-po.md) | Rajnish Mago | | 51 | [Session] [WAKING UP TO EXCESSIVE DAYTIME SLEEPINESS IN PSYCHIATRY AND HOW TO MAKE WEARABLES WORK FOR MEASURING SLEEP AND ACTIVITY](051-waking-up-to-excessive-daytime-sleepiness-in-psychiatry-and.md) | Manish Jha | | 52 | [SLEEP ASSESSMENTS AS PREDICTORS OF HEALTH RISK AND DEPRESSION](052-sleep-assessments-as-predictors-of-health-risk-and-depressio.md) | Emmanuel Mignot | | 53 | [SMARTWATCH MEASUREMENTS AND CONTROLLED DEPRESSION: COMPARATIVE ANALYSES ON PHYSICAL ACTIVITY AND SLEEP](053-smartwatch-measurements-and-controlled-depression-comparativ.md) | Arjun Athreya | | 54 | [PMCID: PMC9008579. SLEEP AND ITS UTILITY FOR MENTAL HEALTH AND WELL-BEING RESEARCH: THE CASE FOR LONGITUDINAL MEASUREMENTS](054-pmcid-pmc9008579-sleep-and-its-utility-for-mental-health-and.md) | Milica Barac | | 55 | [Session] [DEPLOYING ARTIFICIAL INTELLIGENCE (AI) AND LARGE LANGUAGE MODELS (LLMS) IN PSYCHIATRY DRUG DEVELOPMENT](055-deploying-artificial-intelligence-ai-and-large-language-mode.md) | Daniel Karlin | | 56 | [Session] [DESIGNING THE NEXT GENERATION OF STUDIES OF PSYCHEDELICS FOR DIFFICULT TO TREAT DEPRESSION](056-designing-the-next-generation-of-studies-of-psychedelics-for.md) | Michael E. Thase | | 57 | [USING NEUROIMAGING TO ELUCIDATE PSYCHEDELIC MECHANISMS OF ACTION ON BRAIN CIRCUITS](057-using-neuroimaging-to-elucidate-psychedelic-mechanisms-of-ac.md) | Yvette Sheline | | 58 | [LONG TERM OUTCOMES FROM PSILOCYBIN AND RESPONSE TO RE-DOSING FOR DIFFICULT TO TREAT DEPRESSION](058-long-term-outcomes-from-psilocybin-and-response-to-re-dosing.md) | Trisha Suppes | | 59 | [CRITICAL METHODOLOGICAL DECISIONS IN PSYCHEDELIC DRUG TRIALS](059-critical-methodological-decisions-in-psychedelic-drug-trials.md) | Maurizio Fava | | 60 | [REGULATORY PLENARY: AI-BASED TOOLS IN CNS DRUG DEVELOPMENT: A REGULATORY FRAMEWORK FOR CLINICAL TRIAL APPLICATIONS](060-regulatory-plenary-ai-based-tools-in-cns-drug-development-a.md) | Tiffany Farchione | | 61 | [ASCP LIFETIME AWARDEE TALK AND NASRALLAH AWARDEE](061-ascp-lifetime-awardee-talk-and-nasrallah-awardee.md) | Joseph Goldberg | | 62 | [THE TYRANNY OF THE P-VALUE: EFFECT SIZE MATTERS](062-the-tyranny-of-the-p-value-effect-size-matters.md) | Leslie Citrome | | 63 | [A SHORT JOURNEY THROUGH A 50 YEARS OF PROGRESS IN THE TREATMENT OF DEPRESSION](063-a-short-journey-through-a-50-years-of-progress-in-the-treatm.md) | Michael E. Thase | | 64 | [CLINICAL UPDATES ON NEUROTHERAPEUTICS: DISEASE STATE](064-clinical-updates-on-neurotherapeutics-disease-state.md) | Joseph Goldberg | | 65 | [SGAS VS MOOD STABILIZERS: THE PARADIGM SHIFT IN CORE TREATMENT FOR BIPOLAR DISORDER](065-sgas-vs-mood-stabilizers-the-paradigm-shift-in-core-treatmen.md) | Joseph Goldberg | | 66 | [AN UPDATE ON BIPOLAR DISORDER: EVIDENCE, CHALLENGES, AND SOLUTIONS](066-an-update-on-bipolar-disorder-evidence-challenges-and-soluti.md) | Andrew Nierenberg | | 67 | [THE PHARMACOLOGIC TREATMENT OF SCHIZOPHRENIA: STATUS REPORT](067-the-pharmacologic-treatment-of-schizophrenia-status-report.md) | John Kane | | 68 | [EXCITING NEW FINDINGS FROM CLINICAL TRIALS IN THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER](068-exciting-new-findings-from-clinical-trials-in-the-treatment.md) | Lori Davis | | 69 | [SCHIZOPHRENIA POLYGENIC RISK IS NEGATIVELY ASSOCIATED WITH BODY MASS INDEX IN TWO POPULATION COHORTS](069-schizophrenia-polygenic-risk-is-negatively-associated-with-b.md) | Olaoluwa Okusaga1 | | 70 | [RETROSPECTIVE ANALYSIS OF REAL-WORLD TRANSITION STRATEGIES FOR XANOMELINE AND TROSPIUM CHLORIDE IN ADULT PATIENTS WITH SCHIZOPHRENIA](070-retrospective-analysis-of-real-world-transition-strategies-f.md) | Christen Kutz1 | | 71 | [SLEEP ESTIMATION FROM LOW-FREQUENCY SMARTPHONE SENSORS VIA BAYESIAN HIDDEN MARKOV MODEL](071-sleep-estimation-from-low-frequency-smartphone-sensors-via-b.md) | Jin Soo Byun1 | | 72 | [NEURAL AND BEHAVIORAL EVIDENCE FROM REINFORCEMENT LEARNING CONVERGE IN SUPPORT OF RELAXED BELIEFS UNDER LSD](072-neural-and-behavioral-evidence-from-reinforcement-learning-c.md) | Jonathan Kanen1 | | 73 | [AUGMENTING DORSOLATERAL PREFRONTAL CORTEX-TARGETED TDCS WITH COGNITIVE REAPPRAISAL IN COCAINE USE DISORDER](073-augmenting-dorsolateral-prefrontal-cortex-targeted-tdcs-with.md) | Yuefeng Huang1 | | 74 | [MIXED AMPHETAMINE SALTS AND LISDEXAMFETAMINE AS ADJUNCTIVE TREATMENT FOR BIPOLAR DEPRESSION: POOLED ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS](074-mixed-amphetamine-salts-and-lisdexamfetamine-as-adjunctive-t.md) | Mark Frye1 | | 75 | [BRAIN-TO-BRAIN MOVIE NEUROFEEDBACK REDUCES CRAVING IN OPIOID USE DISORDER](075-brain-to-brain-movie-neurofeedback-reduces-craving-in-opioid.md) | Natalie McClain1 | | 76 | [33959050; PMCID: PMC8093505.](076-33959050-pmcid-pmc8093505.md) | Goodman DW | | 77 | [EVALUATING HEPATIC EFFECTS OF SERIAL KETAMINE INFUSIONS FOR TREATMENT-RESISTANT BIPOLAR DEPRESSION](077-evaluating-hepatic-effects-of-serial-ketamine-infusions-for.md) | Gabrielle Lovell1 | | 78 | [DRUG LIKING AND CRAVING OF INTRAVENOUS KETAMINE WHEN PRESCRIBED FOR THE TREATMENT OF MOOD DISORDERS IN A MONITORED SETTING: A DESCRIPTIVE ANALYSIS](078-drug-liking-and-craving-of-intravenous-ketamine-when-prescri.md) | Shreya Vasudeva1 | | 79 | [COMBINED KETAMINE AND COGNITIVE BEHAVIORAL THERAPY: LEVERAGING METAPLASTICITY TO ENHANCE OUTCOMES](079-combined-ketamine-and-cognitive-behavioral-therapy-leveragin.md) | Songjun Li1 | | 80 | [REPEATED KETAMINE INFUSIONS FOR TREATMENT-RESISTANT BIPOLAR DEPRESSION: A RANDOMIZED, MIDAZOLAM-CONTROLLED CLINICAL TRIAL](080-repeated-ketamine-infusions-for-treatment-resistant-bipolar.md) | Diana Orsini1 | | 81 | [10.1177/20451253231202723. PMID: 37771417; PMCID: PMC10524067.](081-10-1177-20451253231202723-pmid-37771417-pmcid-pmc10524067.md) | Fancy F | | 82 | [AMPA RECEPTOR BINDING POTENTIAL IS REDUCED IN THE ANTERIOR CINGULATE CORTEX OF FEMALE PATIENTS WITH PTSD](082-ampa-receptor-binding-potential-is-reduced-in-the-anterior-c.md) | Nicholas Murphy1 | | 83 | [PMID: 31959988.](083-pmid-31959988.md) | Nair J | | 84 | [DURABILITY OF TMS TREATMENT FOR VETERANS WITH MDD EXAMINED VIA SIGNIFICANT PSYCHIATRIC EVENTS ASSOCIATED WITH RELAPSE (SPEAR): A PROPOSED NEW COMPOSITE OUTCOME MEASURE FOR HIGH SEVERITY/LOW FREQUENCY MENTAL HEALTH EVENTS](084-durability-of-tms-treatment-for-veterans-with-mdd-examined-v.md) | Zachary Zuschlag1 | | 85 | [IS BRAIN INSULIN ACTION IMPLICATED IN THE BIOLOGY OF DEPRESSION? A PILOT NEUROIMAGING STUDY IN ADOLESCENTS](085-is-brain-insulin-action-implicated-in-the-biology-of-depress.md) | Kateryna Maksyutynska1 | | 86 | [SEMAGLUTIDE IMPROVES HEALTH-RELATED QUALITY OF LIFE IN MAJOR DEPRESSIVE DISORDER INDEPENDENT OF MOOD CHANGE: EVIDENCE FOR METABOLIC AND MOTIVATIONAL PATHWAYS](086-semaglutide-improves-health-related-quality-of-life-in-major.md) | Cristian-Daniel Llach Lopez1 | | 87 | [MOVING BEYOND SLEEP: THE BROADER CONNECTION BETWEEN THE OREXIN SYSTEM AND PSYCHIATRIC DISORDERS](087-moving-beyond-sleep-the-broader-connection-between-the-orexi.md) | Emmanuel Mignot | | 88 | [INCORPORATING NOVEL MUSCARINIC AGENTS FOR SCHIZOPHRENIA INTO CLINICAL PRACTICE: OVERCOMING CLINICAL INERTIA](088-incorporating-novel-muscarinic-agents-for-schizophrenia-into.md) | Jose Rubio | | 89 | [6736(25)02365-7. PMID: 41763745](089-6736-25-02365-7-pmid-41763745.md) | Kaul I | | 90 | [AI BEYOND EVIL ROBOTS: ENSURING TRANSFORMATIVE MEANS BETTER](090-ai-beyond-evil-robots-ensuring-transformative-means-better.md) | Tiffany Farchione | | 91 | [UPDATE FROM FEDERAL AND OTHER FUNDING AGENCIES](091-update-from-federal-and-other-funding-agencies.md) | Anita Clayton | | 92 | [NIAAA UPDATE: FOCUS ON THE MEDICATIONS DEVELOPMENT PROGRAM](092-niaaa-update-focus-on-the-medications-development-program.md) | Daniel Falk | | 93 | [PATIENT-CENTERED COMPARATIVE EFFECTIVENESS RESEARCH](093-patient-centered-comparative-effectiveness-research.md) | Yu-Ping Wang | | 94 | [ADVANCING THERAPEUTICS FOR SUBSTANCE USE DISORDERS THROUGH NIDA’S THERAPEUTICS DEVELOPMENT PROGRAM](094-advancing-therapeutics-for-substance-use-disorders-through-n.md) | Ivan Montoya | | 95 | [PMID: 40395395; PMCID: PMC12089859. UPDATE FROM DEFENSE HEALTH AGENCY PSYCHOLOGICAL HEALTH RESEARCH PORTFOLIO](095-pmid-40395395-pmcid-pmc12089859-update-from-defense-health-a.md) | Fuad Issa | | 96 | [UPDATES FROM VETERAN HEALTH ADMINISTRATION (VA) RESEARCH INITIATIVES](096-updates-from-veteran-health-administration-va-research-initi.md) | Lori Davis | | 97 | [NIMH UPDATE](097-nimh-update.md) | Matthew Rudorfer | | 98 | [Session] [DURABILITY OUTCOMES IN TREATMENT RESISTANT DEPRESSION](098-durability-outcomes-in-treatment-resistant-depression.md) | Scott Aaronson | | 99 | [TRANSCRANIAL MAGNETIC STIMULATION: DURABILITY OF ANTI-DEPRESSANT RESPONSE](099-transcranial-magnetic-stimulation-durability-of-anti-depress.md) | Saydra Wilson | | 100 | [DURABILITY OF VAGUS NERVE STIMULATION TREATMENT-RESISTANT DEPRESSION: NEW, MORE COMPREHENSIVE FINDINGS FROM THE RECOVER TRIAL](100-durability-of-vagus-nerve-stimulation-treatment-resistant-de.md) | Charles Conway | | 101 | [BEYOND THE ACUTE COURSE: EXPLORING THE DURABILITY OF KETAMINE'S ANTIDEPRESSANT EFFECTS IN THE MAINTENANCE PHASE OF TREATMENT](101-beyond-the-acute-course-exploring-the-durability-of-ketamine.md) | Joshua Rosenblat | | 102 | [15. PMID: 40834563.](102-15-pmid-40834563.md) | Zaki N | | 103 | [40319349; PMCID: PMC12143125. HOW DURABLE ARE ACUTE EFFECTS OF PSILOCYBIN ON TREATMENT-RESISTANT DEPRESSION?](103-40319349-pmcid-pmc12143125-how-durable-are-acute-effects-of.md) | Trisha Suppes | | 104 | [Session] [EVOLVING UNDERSTANDINGS OF PSYCHEDELICS IN CLINICAL RESEARCH](104-evolving-understandings-of-psychedelics-in-clinical-research.md) | Francisco Moreno | | 105 | [UNDERSTANDING PSILOCYBIN ADMINISTRATION: DOSE, PARTICIPANT CHARACTERISTICS, AND THERAPEUTIC CONTEXT](105-understanding-psilocybin-administration-dose-participant-cha.md) | Namik Kirlic | | 106 | [RECRUITING, RETAINING, AND TAILORING PSYCHEDELIC CLINICAL TRIALS FOR VULNERABLE POPULATIONS](106-recruiting-retaining-and-tailoring-psychedelic-clinical-tria.md) | Peter Hendricks | | 107 | [EVALUATING THE CLINICAL UTILITY OF PSILOCYBIN THERAPY VERSUS OTHER PSYCHEDELIC DRUG INTERVENTIONS FOR THE TREATMENT OF POSTTRAUMATIC STRESS DISORDER](107-evaluating-the-clinical-utility-of-psilocybin-therapy-versus.md) | Brandon Weiss | | 108 | [BUILDING COLLABORATIVE CAPACITY IN EARLY CAREER PSYCHOPHARMACOLOGY: STRATEGIES FOR EFFECTIVE PARTNERSHIPS ACROSS ACADEMIA, INDUSTRY, AND CLINICAL PRACTICE](108-building-collaborative-capacity-in-early-career-psychopharma.md) | Keren Bachi | | 109 | [THE EVOLVING NATURE OF ACADEMIC-INDUSTRY PARTNERSHIPS](109-the-evolving-nature-of-academic-industry-partnerships.md) | Mark Rapaport | | 110 | [PMCID: PMC11000613 TAKE-AWAYS FROM MY EXPERIENCE STARTING OUT IN CLINICAL PSYCHOPHARMACOLOGY RESEARCH](110-pmcid-pmc11000613-take-aways-from-my-experience-starting-out.md) | Anita Clayton | | 111 | [10.1056/NEJM1994052633021131530 – 1533 WHY DO WE NEED TEAM SCIENCE APPROACHES IN NEUROBIOLOGICAL AND CLINICAL STUDIES](111-10-1056-nejm1994052633021131530-1533-why-do-we-need-team-sci.md) | Vilma Gabbay | | 112 | [39171416; PMCID: PMC11652247.](112-39171416-pmcid-pmc11652247.md) | Gabbay V. | | 113 | [03008-5. PMID: 39054336; PMCID: PMC11272929. DEVELOPMENT OF ESKETAMINE. AN ACADEMIC -INDUSTRY DREAM COLLABORATION](113-03008-5-pmid-39054336-pmcid-pmc11272929-development-of-esket.md) | Jaskaran Singh | | 114 | [ARE EARLY CAREER CLINICAL RESEARCHERS IN PSYCHIATRY AN ENDANGERED SPECIES?](114-are-early-career-clinical-researchers-in-psychiatry-an-endan.md) | Dan Iosifescu | | 115 | [THE YOUNG INVESTIGATOR AS A PLURIPOTENT STEM CELL: THE ROLE OF INDUSTRY-ACADEMIC PARTNERSHIPS IN A SUCCESSFUL CAREER](115-the-young-investigator-as-a-pluripotent-stem-cell-the-role-o.md) | Charles Nemeroff | | 116 | [COMMUNICATION AND CONFLICT MANAGEMENT: PRACTICAL TOOLS FOR EFFECTIVE LEADERSHIP IN RESEARCH](116-communication-and-conflict-management-practical-tools-for-ef.md) | Ynhi Thomas | | 117 | [ADVANCES IN DEPRESSION RESEARCH: A TRIBUTE TO NOLAN WILLIAMS](117-advances-in-depression-research-a-tribute-to-nolan-williams.md) | Charles Nemeroff | | 118 | [UNDERSTANDING AND HARNESSING THE OPIOID EFFECTS OF KETAMINE](118-understanding-and-harnessing-the-opioid-effects-of-ketamine.md) | Alan Schatzberg | | 119 | [NON-INVASIVE AMYGDALA NEUROMODULATION IN HUMANS WITH FOCUSED ULTRASOUND: NEUROBIOLOGICAL AND CLINICAL EFFECTS IN MOOD, ANXIETY, AND TRAUMA-RELATED DISORDERS](119-non-invasive-amygdala-neuromodulation-in-humans-with-focused.md) | Gregory Fonzo | | 120 | [CLINICAL AND NEURAL OUTCOMES OF MAGNESIUM-IBOGAINE FOR TRAUMATIC BRAIN INJURY IN SPECIAL OPERATIONS FORCES VETERANS](120-clinical-and-neural-outcomes-of-magnesium-ibogaine-for-traum.md) | Ian Kratter | | 121 | [Session] [PHOTOBIOMODULATION WITH NEAR INFRARED LIGHT: A NOVEL TREATMENT FOR PSYCHIATRIC DISORDERS](121-photobiomodulation-with-near-infrared-light-a-novel-treatmen.md) | Dan Iosifescu | | 122 | [DOSE-DEPENDENT EFFECTS OF TRANSCRANIAL PHOTOBIOMODULATION ON BRAIN TEMPERATURE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A SPECTROSCOPY STUDY](122-dose-dependent-effects-of-transcranial-photobiomodulation-on.md) | Paolo Cassano | | 123 | [6. PMID: 39370461. TRANSCRANIAL PHOTOBIOMODULATION FOR ALZHEIMER'S DISEASE](123-6-pmid-39370461-transcranial-photobiomodulation-for-alzheime.md) | Dan Iosifescu | | 124 | [TRANSCRANIAL INFRARED LASER STIMULATION IMPROVES COGNITIVE PERFORMANCE AND INDUCES A BIPHASIC CEREBRAL PERFUSION RESPONSE IN REMITTED BIPOLAR DISORDER](124-transcranial-infrared-laser-stimulation-improves-cognitive-p.md) | Jorge Almeida | | 125 | [UNCOVERING MECHANISMS OF PHOTOBIOMODULATION BEHIND CLINICAL CHANGES: EVIDENCE FROM NEUROIMAGING](125-uncovering-mechanisms-of-photobiomodulation-behind-clinical.md) | Naomi Gaggi | | 126 | [Session] [LESSONS FROM TRANSFORMING THE PSYCHIATRIC HEALTHCARE SYSTEM: HOW TO IMPROVE OUTCOMES?](126-lessons-from-transforming-the-psychiatric-healthcare-system.md) | Andrew Nierenberg | | 127 | [ALIGNMENT FOR PROGRESS: A MOVEMENT TO BRING CHANGE](127-alignment-for-progress-a-movement-to-bring-change.md) | Nathaniel Counts | | 128 | [ONE EXPERT BY EXPERIENCE JOURNEY](128-one-expert-by-experience-journey.md) | George McAllister | | 129 | [CHALLENGES OF BUILDING A LEARNING HEALTH SYSTEM FOR EARLY PSYCHOSIS CARE](129-challenges-of-building-a-learning-health-system-for-early-ps.md) | Lisa B Dixon | | 130 | [TRANSFORMING THE HEALTHCARE SYSTEM WITH THE BIPOLAR ACTION NETWORK](130-transforming-the-healthcare-system-with-the-bipolar-action-n.md) | Andrew Nierenberg | | 131 | [Session] [DEVELOPING TREATMENTS FOR THE NON-MOTOR SYMPTOMS OF PARKINSON'S DISEASE](131-developing-treatments-for-the-non-motor-symptoms-of-parkinso.md) | Gerard Sanacora | | 132 | [AB-300, A NOVEL 5-HT2A/2C AGONIST, REVERSES MOTIVATIONAL DEFICITS IN A TETRABENAZINE MODEL OF PARKINSON’S DISEASE APATHY](132-ab-300-a-novel-5-ht2a-2c-agonist-reverses-motivational-defic.md) | Daniel Jeffries | | 133 | [PSILOCYBIN THERAPY FOR DEPRESSION IN PARKINSON’S DISEASE](133-psilocybin-therapy-for-depression-in-parkinson-s-disease.md) | Ellen Bradley | | 134 | [TARGETING SYNAPTIC LOSS IN PARKINSON’S DISEASE DEPRESSION WITH KETAMINE](134-targeting-synaptic-loss-in-parkinson-s-disease-depression-wi.md) | Sophie Holmes | | 135 | [ARTIFICIAL INTELLIGENCE: UNDERSTANDING THE PRESENT AND ANTICIPATING THE FUTURE](135-artificial-intelligence-understanding-the-present-and-antici.md) | Valentina Mantua | | 136 | [USING ARTIFICIAL INTELLIGENCE AND SOCIAL MEDIA DATA FOR POPULATION MENTAL HEALTH SURVEILLANCE](136-using-artificial-intelligence-and-social-media-data-for-popu.md) | Yulin Hswen | | 137 | [ASSESSING AI FOR CLINICAL CARE AND RESEARCH](137-assessing-ai-for-clinical-care-and-research.md) | John Torous | | 138 | [BRIDGING AI INNOVATION AND CLINICAL TRIAL DATA IN PSYCHIATRY: MATHEMATICAL LIMITS AND CLINICAL CONSEQUENCES](138-bridging-ai-innovation-and-clinical-trial-data-in-psychiatry.md) | Joseph Geraci | | 139 | [Session] [WHAT TO KNOW ABOUT KETAMINE SAFETY: PATIENT MONITORING, NEUROTOXICITY, AND CONSIDERATIONS FOR SPECIAL PATIENT POPULATIONS](139-what-to-know-about-ketamine-safety-patient-monitoring-neurot.md) | Benjamin Brody | | 140 | [RACEMIC KETAMINE SIDE EFFECTS, ADVERSE REACTIONS, AND MONITORING](140-racemic-ketamine-side-effects-adverse-reactions-and-monitori.md) | Benjamin Brody | | 141 | [KETAMINE FOR DEPRESSION, BUT AT WHAT COST? EVIDENCE FOR NEUROTOXICITY FROM HUMAN AND ANIMAL STUDIES](141-ketamine-for-depression-but-at-what-cost-evidence-for-neurot.md) | Samuel Wilkinson | | 142 | [USE OF KETAMINE FOR DEPRESSION IN SPECIAL POPULATIONS](142-use-of-ketamine-for-depression-in-special-populations.md) | Joshua Rosenblat | | 143 | [Session] [THE DISCOVERY AND CLINICAL DEVELOPMENT OF (2R,6R)- HYDROXYNORKETAMINE FOR DEPRESSION AND PAIN](143-the-discovery-and-clinical-development-of-2r-6r-hydroxynorke.md) | Todd Gould | | 144 | [FROM KETAMINE METABOLITE TO CANDIDATE THERAPEUTIC: PRECLINICAL DISCOVERY OF (2R,6R)-HNK RELEVANCE TO DEPRESSION TREATMENT](144-from-ketamine-metabolite-to-candidate-therapeutic-preclinica.md) | Todd Gould | | 145 | [PRECLINICAL DEVELOPMENT OF (2R,6R)-HYDROXYNORKETAMINE FOR HUMAN CLINICAL EVALUATION](145-preclinical-development-of-2r-6r-hydroxynorketamine-for-huma.md) | Craig Thomas | | 146 | [CLINICAL DEVELOPMENT OF (2R,6R)-HYDROXYNORKETAMINE: ONGOING TRIALS IN TRD AND OCD AND PHASE 1 SAFETY, TOLERABILITY, AND PK/PD RESULTS IN HEALTHY VOLUNTEERS](146-clinical-development-of-2r-6r-hydroxynorketamine-ongoing-tri.md) | Carlos Zarate | | 147 | [EVALUATION OF THE (2R,6R)-HYDROXYNORKETAMINE AS A POTENTIAL CLINICAL USEFUL ANALGESIC AGENT: TRANSLATIONAL EXPERIENCE FROM PRECLINICAL TO HUMAN STUDY](147-evaluation-of-the-2r-6r-hydroxynorketamine-as-a-potential-cl.md) | Robert McCarthy | | 148 | [Session] [NEW AND ANTICIPATED INTERVENTIONS FOR PERINATAL DEPRESSION](148-new-and-anticipated-interventions-for-perinatal-depression.md) | Anita Clayton | | 149 | [PATHOPHYSIOLOGICAL MECHANISMS OF PERINATAL DEPRESSION](149-pathophysiological-mechanisms-of-perinatal-depression.md) | Kristina Deligiannidis | | 150 | [EPIGENETIC BIOMARKERS IN POSTPARTUM DEPRESSION AND POSTPARTUM PSYCHOSIS](150-epigenetic-biomarkers-in-postpartum-depression-and-postpartu.md) | Jennifer Payne | | 151 | [APPROVED AND POTENTIAL TREATMENTS FOR PPD](151-approved-and-potential-treatments-for-ppd.md) | Anita Clayton | | 152 | [ADDICTION AND NEUROMODULATION IN PREGNANCY](152-addiction-and-neuromodulation-in-pregnancy.md) | Rana Jawish | | 153 | [THE FUTURE DSM: DESIGNING A SCIENTIFIC, INCLUSIVE, AND PRACTICAL DIAGNOSTIC MANUAL FOR MODERN PSYCHIATRY](153-the-future-dsm-designing-a-scientific-inclusive-and-practica.md) | Nitin Gogtay | | 154 | [THE FUTURE DSM: DESIGNING A SCIENTIFIC, INCLUSIVE, AND PRACTICAL DIAGNOSTIC MANUAL FOR MODERN PSYCHIATRY](154-the-future-dsm-designing-a-scientific-inclusive-and-practica.md) | Jonathan Alpert | | 155 | [STRUCTURE AND DIMENSIONS SUBCOMMITTEE](155-structure-and-dimensions-subcommittee.md) | Dost Ongur | | 156 | [THE DSM SUBCOMMITTEE ON CANDIDATE BIOMARKERS AND BIOLOGICAL FACTORS](156-the-dsm-subcommittee-on-candidate-biomarkers-and-biological.md) | Anissa Abi Dargham | | 157 | [REGULATORY CHALLENGES: ASK THE EXPERTS](157-regulatory-challenges-ask-the-experts.md) | Tiffany Farchione | | 158 | [W1. THE PHASE 2/3 GAIN TRIAL OF THE FIRST-GENERATION P. GINGIVALIS GINGIPAIN INHIBITOR ATUZAGINSTAT IN MILD-TO-MODERATE PROBABLE ALZHEIMER’S DISEASE: NEW CEREBROSPINAL FLUID BIOMARKER DATA](158-w1-the-phase-2-3-gain-trial-of-the-first-generation-p-gingiv.md) | Michael Detke1 | | 159 | [W2. GALANTAMINE-MEMANTINE COMBINATION REGULATING THE KYNURENINE PATHWAY METABOLISM IN THE TREATMENT OF POST-STROKE DEPRESSION AND POST-STROKE COGNITIVE IMPAIRMENTS AND PREVENTION OF STROKE](159-w2-galantamine-memantine-combination-regulating-the-kynureni.md) | Anne Khodarkovskaya1 | | 160 | [W3. DYNAMIC CAUSAL MODELING OF TRIPLE-NETWORK CONNECTIVITY VARIES BY SUICIDE ATTEMPT HISTORY](160-w3-dynamic-causal-modeling-of-triple-network-connectivity-va.md) | Benjamin Chandler1 | | 161 | [W4. A REVIEW OF EVIDENCE AND AN ALGORITHM FOR USE OF PSYCHOPHARMACOLOGY IN THE TREATMENT OF TOBACCO USE DISORDER IN BEHAVIORAL HEALTH SETTINGS](161-w4-a-review-of-evidence-and-an-algorithm-for-use-of-psychoph.md) | Afrah Mohammad1 | | 162 | [W5. EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS IN SUBSTANCE USE DISORDERS WITH MEMANTINE, GALANTAMINE, N-ACETYLCYSTEINE, AND DOXAZOSIN/PRAZOSIN](162-w5-evidence-from-randomized-controlled-trials-in-substance-u.md) | Kristine Hawkins1 | | 163 | [W6. CHANGES IN SMOKING-RELATED OUTCOMES WITH TIRZEPATIDE IN INDIVIDUALS WITH METHAMPHETAMINE USE DISORDER WHO SMOKE](163-w6-changes-in-smoking-related-outcomes-with-tirzepatide-in-i.md) | Nandini Jha1 | | 164 | [W7. CHANGES IN DEPRESSIVE SYMPTOMS WITH TIRZEPATIDE IN INDIVIDUALS WITH MODERATE-TO-SEVERE METHAMPHETAMINE USE DISORDER](164-w7-changes-in-depressive-symptoms-with-tirzepatide-in-indivi.md) | Virgilio Garza1 | | 165 | [W8. SAFETY AND TOLERABILITY OF 32-WEEK-LONG TREATMENT WITH TIRZEPATIDE IN INDIVIDUALS WITH MODERATE-TO-SEVERE METHAMPHETAMINE USE DISORDER](165-w8-safety-and-tolerability-of-32-week-long-treatment-with-ti.md) | Amrita Ghose1 | | 166 | [W9. FIRST DOSE TREATMENT EFFECTS WITH INJECTABLE WEEKLY AND MONTHLY BUPRENORPHINE (CAM2038) AND THE RELATIONSHIP BETWEEN BUPRENORPHINE PLASMA CONCENTRATIONS AND WITHDRAWAL SUPPRESSION IN PARTICIPANTS WITH OPIOID USE DISORDER](166-w9-first-dose-treatment-effects-with-injectable-weekly-and-m.md) | Michael P. Frost1 | | 167 | [W10. A NEW DAWN FOR SOCIAL ANXIETY TREATMENT: CLINICAL ADVANCEMENT OF THE NOVEL V1AR ANTAGONIST, NTX-1472](167-w10-a-new-dawn-for-social-anxiety-treatment-clinical-advance.md) | Tiffany Lago1 | | 168 | [W11. TREATMENT PATTERNS AMONG INCIDENT AND PERSISTENT PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD)](168-w11-treatment-patterns-among-incident-and-persistent-patient.md) | Erin Ferries1 | | 169 | [W12. THE IMPACT OF COMORBID PSYCHIATRIC DISORDERS ON MISCONDUCTS AMONG INCARCERATED INDIVIDUALS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: A PRELIMINARY STUDY](169-w12-the-impact-of-comorbid-psychiatric-disorders-on-miscondu.md) | Elssa Toumeh1 | | 170 | [W13. THE NEUROCHEMICAL AND ANXIOLYTIC-LIKE EFFECTS OF CENTANAFADINE IN PRECLINICAL ASSAYS IN THE RAT AND MOUSE](170-w13-the-neurochemical-and-anxiolytic-like-effects-of-centana.md) | Reem Elbekai1 | | 171 | [W14. GROWING TREND OF STIMULANT USE IN YOUNG PATIENTS MISDIAGNOSED WITH ADHD: A CASE-BASED SYSTEMATIC REVIEW](171-w14-growing-trend-of-stimulant-use-in-young-patients-misdiag.md) | James Chua1 | | 172 | [W15. EMOTIONAL DYSREGULATION SYMPTOM OUTCOMES IN ADULTS WITH ADHD TREATED WITH CENTANAFADINE: A POOLED POST HOC ANALYSIS OF TWO PHASE 3 TRIALS](172-w15-emotional-dysregulation-symptom-outcomes-in-adults-with.md) | Jeffrey Newcorn1 | | 173 | [W16. THE PERSISTENCE OF NEUROEPITHELIAL PROGENITORS IN NEOCORTICAL ORGANOIDS: IMPEDING ACCURATE MODELS FOR DRUG SCREENING IN NEURODEVELOPMENTAL DISORDERS](173-w16-the-persistence-of-neuroepithelial-progenitors-in-neocor.md) | Konstantina Psychogyiou1 | | 174 | [W17. LONG-TERM SAFETY AND TOLERABILITY OF CARIPRAZINE IN PEDIATRIC PATIENTS WITH AUTISM SPECTRUM DISORDER, BIPOLAR I DISORDER OR SCHIZOPHRENIA: FINAL RESULTS FROM AN OPEN-LABEL STUDY](174-w17-long-term-safety-and-tolerability-of-cariprazine-in-pedi.md) | Marshall B. Lucas1 | | 175 | [W18. E2086, A SELECTIVE OREXIN RECEPTOR-2 AGONIST: STUDY FOR PROMOTING WAKEFULNESS IN PATIENTS WITH NARCOLEPSY TYPE 1](175-w18-e2086-a-selective-orexin-receptor-2-agonist-study-for-pr.md) | Bruce Corser1 | | 176 | [W19. THE COMPLEX MULTI-SYSTEM SYMPTOM INVENTORY (COMSS): A NEW INSTRUMENT TO ASSESS SYMPTOM FREQUENCY, IMPACT, AND POSTURAL DEPENDENCE ACROSS MULTIPLE CENTRAL AND PERIPHERAL AUTONOMIC SYMPTOM DOMAINS](176-w19-the-complex-multi-system-symptom-inventory-comss-a-new-i.md) | Christine Cheah1 | | 177 | [W20. STATIC AND DYNAMIC DISRUPTIONS OF SALIENCE-NETWORK FLEXIBILITY IN VETERANS WITH COMORBID MILD TBI AND ALCOHOL USE DISORDER](177-w20-static-and-dynamic-disruptions-of-salience-network-flexi.md) | Niki Sabetfakhri1 | | 178 | [W21. SUCCESSFUL EARLY TREATMENT OF ANTI-N-METHYL-D-ASPARTATE RECEPTOR ENCEPHALITIS ASSOCIATED WITH SMALL CELL LUNG CANCER IN AN ELDERLY MALE PATIENT: A CASE REPORT](178-w21-successful-early-treatment-of-anti-n-methyl-d-aspartate.md) | Yuya Honda1 | | 179 | [W22. GH001 EFFICACY IS INDEPENDENT OF PRIOR ANTIDEPRESSANT TREATMENT FAILURES IN TREATMENT-RESISTANT DEPRESSION: A POST HOC ANALYSIS OF A PHASE 2B RANDOMIZED CONTROLLED TRIAL](179-w22-gh001-efficacy-is-independent-of-prior-antidepressant-tr.md) | Michael E. Thase1 | | 180 | [W23. EXAMINING THE IMPACT OF PATIENT-CENTERED APPROACHES ON THE ASSESSMENT AND MANAGEMENT OF COGNITIVE IMPAIRMENT IN MAJOR DEPRESSIVE DISORDER](180-w23-examining-the-impact-of-patient-centered-approaches-on-t.md) | Michael E. Thase1 | | 181 | [W24. SELTOREXANT VERSUS QUETIAPINE EXTENDED RELEASE AS ADJUNCTIVE TREATMENT IN MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS: PHASE 3 TRIAL](181-w24-seltorexant-versus-quetiapine-extended-release-as-adjunc.md) | Yanina Flossbach1 | | 182 | [W25. BENEFITS OF ADJUNCTIVE VAGUS NERVE STIMULATION IN DIFFICULT-TO-TREAT DEPRESSION: OUTCOMES OF A NATURALISTIC EUROPEAN COHORT (RESTORE-LIFE) COMPARED TO THE USA RECOVER RANDOMIZED CONTROLLED TRIAL](182-w25-benefits-of-adjunctive-vagus-nerve-stimulation-in-diffic.md) | R. Hamish McAllister-Williams1 | | 183 | [W26. POOLED INDIVIDUAL PATIENT DATA ANALYSIS OF THREE PHASE 2 TRIALS SUPPORTS VASOPRESSIN V1B RECEPTOR ANTAGONISM (BH-200 250 MG BID) AS AN ANTIDEPRESSANT MECHANISM FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)](183-w26-pooled-individual-patient-data-analysis-of-three-phase-2.md) | Lars Arvastson1 | | 184 | [W27. GENETICALLY DEFINED SUBGROUP ANALYSIS REVEALS DIFFERENTIAL RESPONSE TO VASOPRESSIN V1B ANTAGONISM IN PATIENTS WITH MDD PRE-EXPOSED TO ANTIDEPRESSANT IN THE CURRENT EPISODE: POST-HOC ANALYSIS OF THE PHASE 2 OLIVE TRIAL](184-w27-genetically-defined-subgroup-analysis-reveals-differenti.md) | Caren Strote1 | | 185 | [W28. CHARACTERISTICS OF DEPRESSION EPISODES TO INFORM REAL-WORLD HEALTH STATES FOR MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION](185-w28-characteristics-of-depression-episodes-to-inform-real-wo.md) | Vicki Wing1 | | 186 | [W29. LONGITUDINAL PROFILING OF TREATMENT TRAJECTORIES IN SSRI-ANCHORED MDD USING AGENTIC AI](186-w29-longitudinal-profiling-of-treatment-trajectories-in-ssri.md) | Naveen Deevi1 | | 187 | [W30. DIMENSIONS OF PSYCHEDELIC EXPERIENCE PREDICTING ANTIDEPRESSANT RESPONSE TO PSILOCYBIN ACROSS DIAGNOSES](187-w30-dimensions-of-psychedelic-experience-predicting-antidepr.md) | Andrew van der Vaart1 | | 188 | [W31. ANXIOUS DEPRESSION AS PREDICTOR OF CLINICAL OUTCOMES IN TREATMENT-RESISTANT DEPRESSION (ASCERTAIN-TRD)](188-w31-anxious-depression-as-predictor-of-clinical-outcomes-in.md) | Stefania Chaikali1 | | 189 | [W32. NEUROACTIVE STEROID CHANGES PRE-AND POST-KETAMINE DURING A DOUBLE-BLIND, CROSSOVER CLINICAL TRIAL: AN EXPLORATORY STUDY](189-w32-neuroactive-steroid-changes-pre-and-post-ketamine-during.md) | Hiroe Hu1 | | 190 | [W33. ASSOCIATION OF MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS WITH HEALTHCARE RESOURCE USE AND CARDIOVASCULAR AND METABOLIC CONDITIONS – ANALYSIS OF NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY](190-w33-association-of-major-depressive-disorder-with-insomnia-s.md) | Hrishikesh Kale1 | | 191 | [W34. ESMETHADONE (REL-1017) IN PATIENTS WITH ANTIDEPRESSANT TACHYPHYLAXIS: A POST HOC EFFICACY ANALYSIS IN A PRE-RANDOMIZATION–DEFINED SUBGROUP](191-w34-esmethadone-rel-1017-in-patients-with-antidepressant-tac.md) | Clotilde Guidetti1 | | 192 | [W35. PRECLINICAL BEHAVIORAL AND PHARMACOLOGICAL CHARACTERISTICS OF TN-001, A NOVEL, NON-HALLUCINOGENIC NEUROPLASTOGEN FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER](192-w35-preclinical-behavioral-and-pharmacological-characteristi.md) | Samuel Slocum1 | | 193 | [W36. METABOLIC PROFILE OF ADJUNCTIVE LUMATEPERONE 42 MG IN MAJOR DEPRESSIVE DISORDER: A POOLED ANALYSIS OF 2 RANDOMIZED, PLACEBO-CONTROLLED TRIALS](193-w36-metabolic-profile-of-adjunctive-lumateperone-42-mg-in-ma.md) | Willie R. Earley1 | | 194 | [W37. LUMATEPERONE 42 MG IN MAJOR DEPRESSIVE DISORDER: DEMOGRAPHIC AND CLINICAL SUBGROUPS EFFICACY ANALYSIS IN A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED TRIAL](194-w37-lumateperone-42-mg-in-major-depressive-disorder-demograp.md) | Raffaele Migliore1 | | 195 | [W38. EFFICACY OF LUMATEPERONE 42 MG FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER: ANALYSIS OF DEMOGRAPHIC AND CLINICAL SUBGROUPS IN A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED TRIAL](195-w38-efficacy-of-lumateperone-42-mg-for-the-treatment-of-majo.md) | Suresh Durgam1 | | 196 | [W39. PSYCHOPHARMACOLOGY OF ENX-104: A POTENT DOPAMINE (DA) D2/D3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH ANHEDONIA](196-w39-psychopharmacology-of-enx-104-a-potent-dopamine-da-d2-d3.md) | Robin Geever1 | | 197 | [W40. IMPACT OF GH001 ON DEPRESSIVE SYMPTOMS, ANXIETY, AND QUALITY OF LIFE IN TREATMENT-RESISTANT DEPRESSION: RESULTS FROM A PHASE 2B TRIAL](197-w40-impact-of-gh001-on-depressive-symptoms-anxiety-and-quali.md) | Wiesław J. Cubała1 | | 198 | [W41. RAPID AND SUSTAINED IMPROVEMENT IN ANHEDONIA FOLLOWING INHALED MEBUFOTENIN (GH001) TREATMENT IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION](198-w41-rapid-and-sustained-improvement-in-anhedonia-following-i.md) | Roger McIntyre1 | | 199 | [W42. EFFECTS OF DEXTROMETHORPHAN-BUPROPION (45MG/105MG) IN PARTICIPANTS WITH MAJOR DEPRESSIVE DISORDER AND ANXIOUS DISTRESS](199-w42-effects-of-dextromethorphan-bupropion-45mg-105mg-in-part.md) | Jeffrey Strawn1 | | 200 | [W43. HJ-006: A NON-HALLUCINOGENIC SYNAPTOGENIC COMPOUND WITH RAPID AND SUSTAINED ANTIDEPRESSANT EFFICACY](200-w43-hj-006-a-non-hallucinogenic-synaptogenic-compound-with-r.md) | Li Zeng1 | | 201 | [W45. PSYCHOMOTOR DISTURBANCE AS A PREDICTOR OF TREATMENT RESPONSE IN MOOD DISORDERS: A SYSTEMATIC REVIEW](201-w45-psychomotor-disturbance-as-a-predictor-of-treatment-resp.md) | Sara Di Luch1 | | 202 | [W46. THE MONOTHERAPY ANTIDEPRESSANT PIPELINE PROBLEM: ONLY 8 APPROVALS OUT OF 28 ATTEMPTS IN THE LAST 25 YEARS](202-w46-the-monotherapy-antidepressant-pipeline-problem-only-8-a.md) | Anshu Arora1 | | 203 | [W47. EARLY RESPONSE TO PSILOCYBIN IN ADULTS WITH TREATMENT-RESISTANT DEPRESSION AS A PREDICTOR FOR ANTIDEPRESSANT EFFICACY](203-w47-early-response-to-psilocybin-in-adults-with-treatment-re.md) | Noah Chisamore1 | | 204 | [W48. EARLY MOTIVATIONAL AND HEDONIC RESPONSES TO ANTIDEPRESSANTS IN MAJOR DEPRESSIVE DISORDER: A REAL-WORLD EVIDENCE STUDY](204-w48-early-motivational-and-hedonic-responses-to-antidepressa.md) | Maurice M. Ohayon1 | | 205 | [W49. REAL-WORLD EVIDENCE OF THE CLINICAL AND PREFERENCE IMPACT OF A PRESCRIPTION DIGITAL THERAPEUTIC FOR MAJOR DEPRESSIVE DISORDER: AN ONGOING PROSPECTIVE STUDY IN AN ACADEMIC HEALTH SYSTEM](205-w49-real-world-evidence-of-the-clinical-and-preference-impac.md) | Sarah Small1 | | 206 | [W50. ANXIOLYTIC EFFECTS OF DEXTROMETHORPHAN-BUPROPION (45MG/105MG): POST HOC ANALYSES ACROSS TRIALS IN MAJOR DEPRESSIVE DISORDER](206-w50-anxiolytic-effects-of-dextromethorphan-bupropion-45mg-10.md) | Jeffrey Strawn1 | | 207 | [W51. MULTIMODAL IDENTIFICATION OF NEUROBIOLOGICAL SUBTYPES ASSOCIATED WITH KETAMINE RESPONSE IN TREATMENT-RESISTANT DEPRESSION USING NETRAAI](207-w51-multimodal-identification-of-neurobiological-subtypes-as.md) | Joseph Geraci1 | | 208 | [W52. OREXIN 2 RECEPTOR AGONISTS AS A POTENTIAL THERAPEUTIC APPROACH TO THE TREATMENT OF SLEEP-WAKE DISTURBANCE, FATIGUE, AND COGNITIVE DEFICIT IN NEUROPSYCHIATRIC DISEASE](208-w52-orexin-2-receptor-agonists-as-a-potential-therapeutic-ap.md) | David Plante1 | | 209 | [W53. A NOVEL DISEASE-MODIFYING STRATEGY FOR NARCOLEPSY TYPE 1 – PRECLINICAL RATIONALE AND DEVELOPMENT ROADMAP FOR THE DOXA PLATFORM](209-w53-a-novel-disease-modifying-strategy-for-narcolepsy-type-1.md) | Eric Konofal1 | | 210 | [W54. TARGETED ELIGIBILITY REVIEW CAN DECREASE THE NUMBER OF INAPPROPRIATE PARTICIPANTS ENROLLED IN CLINICAL TRIALS](210-w54-targeted-eligibility-review-can-decrease-the-number-of-i.md) | Chris Mikesell1 | | 211 | [W55. IMPACT-EXT: EVALUATING THE DURABILITY AND REDOSING OF TSND-201 (METHYLONE) FOR THE TREATMENT OF PTSD](211-w55-impact-ext-evaluating-the-durability-and-redosing-of-tsn.md) | Jennifer Warner-Schmidt1 | | 212 | [W56. SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MSD-001 AFTER SINGLE DOSING IN HEALTHY ADULTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY](212-w56-safety-pharmacokinetics-and-pharmacodynamics-of-msd-001.md) | Fas Krol1 | | 213 | [W57. BLINDING INTEGRITY IN PSYCHEDELIC RANDOMIZED CONTROLLED TRIALS: A SYSTEMATIC REVIEW](213-w57-blinding-integrity-in-psychedelic-randomized-controlled.md) | Diana Orsini1 | | 214 | [W58. UNLOCKING MEDICINES FOR NEUROPSYCHIATRY BY ENHANCING ORAL ABSORPTION USING A LYMPHATIC-TARGETING PRODRUG TECHNOLOGY](214-w58-unlocking-medicines-for-neuropsychiatry-by-enhancing-ora.md) | Antony Loebel1 | | 215 | [W59. A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE FATTY ACID AMIDE HYDROLASE INHIBITOR PALMITOYLETHANOLAMIDE IN BIPOLAR DEPRESSION](215-w59-a-randomized-placebo-controlled-trial-of-the-fatty-acid.md) | Rodrigo Machado-Vieira1 | | 216 | [W60. EFFICACY, SAFETY AND TOLERABILITY OF LYSERGIC ACID DIETHYLAMIDE FOR THE TREATMENT OF DEPRESSIVE SYMPTOMS: A META-ANALYSIS AND SYSTEMATIC REVIEW](216-w60-efficacy-safety-and-tolerability-of-lysergic-acid-diethy.md) | Andreea Chiorean1 | | 217 | [(CRD420251063539).](217-crd420251063539.md) |